From an R&D perspective, they've actually got the first or second largest cancer pipeline in the world. So, they're moving in the right direction.
It brings attention back to a lot of the risks in pharmaceuticals right now with regards to drug safety.
The ones that are lost will probably be lost for good.
The most important thing is that Medicare Part D was implemented, and this boost for seniors should make earnings quite buoyant. We think investors will be very pleased with the numbers.
You might have less competitive intensity than you think. It will be competitive, but not to the detriment of players involved. There's room to grow for the entire business, and rising tides will lift all boats.
This drug has a very high likelihood of success.
It's a drop in the bucket. It's helping the stock price today, but gastric cancer is not one of the biggest markets for cancer.
It's very costly for Americans to continue to fatten up.
It left us with a flawed system where they try to get there first and they challenge patents even if they feel they're not going to win. The system is broken.
It's wide open, ... The obesity market is unique in that it is probably the largest market in the world. However, nothing really works well in terms of safety and tolerability.